Mochida Pharmaceutical Co., Ltd. AI Stock Analysis
Want to see JP:4534 full AI Analyst Report?
Mochida Pharmaceutical Co., Ltd. (4534) AI Stock Analysis
Mochida Pharmaceutical Co., Ltd.
(TSE/TYO:4534)
Mochida Pharmaceutical's financial performance is solid, with strong profitability and a robust balance sheet, though cash flow volatility is a concern. The technical picture is mixed, with short-term strength but overbought conditions and long-term resistance. Valuation appears attractive with a low P/E and decent dividend yield. The overall score of 70 reflects a moderately bullish outlook with some caution due to cash flow and technical overbought signals.
Mochida Pharmaceutical Co., Ltd. (4534) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 114.17B
- Dividend Yield
- 2.46%
- Average Volume (3M)
- 44.81K
- Price to Earnings (P/E)
- 11.0
- Beta (1Y)
- 0.64
- Revenue Growth
- 15.85%
- EPS Growth
- 60.55%
- Country
- Japan
- Employees
- 1,479
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuti...
How the Company Makes Money
Mochida Pharmaceutical generates revenue primarily from the sale of pharmaceuticals, especially prescription drugs, to hospitals, clinics, and pharmacies in Japan. Its earnings are driven by (1) sales of its in-house products marketed under the Mochi...
Mochida Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Mochida Pharmaceutical's income statement shows healthy revenue growth (9.9% to ¥116.95B) and net income up 39% to ¥7.9B, with solid margins. The balance sheet is robust with strong equity (¥140.3B) and minimal leverage (debt/equity 0.07). However, cash flow has been inconsistent, with negative operating cash flow in FY2026, raising concerns about cash generation sustainability. Overall financial health is good but tempered by cash flow volatility.
Income Statement
74PositiveBalance Sheet
86Very PositiveCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 126.33B | 116.95B | 105.16B | 102.89B | 103.26B | 110.18B |
| Gross Profit | 59.50B | 56.26B | 53.79B | 52.07B | 55.12B | 59.55B |
| EBITDA | 15.72B | 13.13B | 11.07B | 8.61B | 11.18B | 17.08B |
| Net Income | 10.75B | 7.90B | 5.68B | 4.55B | 6.65B | 10.57B |
Balance Sheet | ||||||
| Total Assets | 184.91B | 182.72B | 163.56B | 162.30B | 161.04B | 165.93B |
| Cash, Cash Equivalents and Short-Term Investments | 28.57B | 31.06B | 51.15B | 46.79B | 60.51B | 61.91B |
| Total Debt | 10.00B | 10.00B | 342.00M | 369.00M | 178.00M | 0 |
| Total Liabilities | 42.56B | 42.39B | 32.87B | 34.33B | 34.26B | 37.28B |
| Stockholders Equity | 142.35B | 140.33B | 130.69B | 127.97B | 126.78B | 128.65B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -10.04B | 7.19B | -9.78B | 5.13B | 4.47B |
| Operating Cash Flow | 0 | -7.35B | 9.35B | -7.48B | 7.30B | 7.46B |
| Investing Cash Flow | 0 | -16.85B | 17.36B | 74.00M | -2.95B | -2.01B |
| Financing Cash Flow | 0 | 7.03B | -2.87B | -6.39B | -6.88B | -5.96B |
Mochida Pharmaceutical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4534, the sentiment is Positive. The current price of 3355.00 is above the 20-day moving average (MA) of 3271.00, above the 50-day MA of 3217.34, and above the 200-day MA of 3327.94, indicating a bullish trend. The MACD of 30.81 indicates Negative momentum. The RSI at 58.69 is Neutral, neither overbought nor oversold. The STOCH value of 58.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4534.
Mochida Pharmaceutical Co., Ltd. Peers Comparison
Overall Rating
- JP:453470Outperform
JP:452164.9Neutral
JP:454764Neutral
JP:488756Neutral
JP:456952Neutral
JP:455346Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4534 | 70Outperform | JPY 114.17B | 11.03 | 7.68% | 2.46% | 15.85% | 60.55% |
| JP:4521 | 65Neutral | JPY 137.77B | 15.83 | 6.11% | 4.97% | 5.43% | 1167.62% |
| JP:4547 | 64Neutral | JPY 158.69B | 14.41 | 4.95% | 5.28% | 5.87% | -21.16% |
| JP:4887 | 56Neutral | JPY 162.36B | 21.60 | ― | 3.44% | 2.43% | ― |
| JP:4569 | 52Neutral | JPY 56.85B | 159.76 | ― | 4.35% | -6.48% | -95.83% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4553 | 46Neutral | JPY 164.62B | 42.20 | 2.10% | 2.39% | 7.06% | -81.10% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3355.00 | 123.57 | 3.82% | |
| JP:4521 | Kaken Pharmaceutical Co | 3825.00 | 314.47 | 8.96% | |
| JP:4547 | Kissei Pharmaceutical Co | 3885.00 | -96.82 | -2.43% | |
| JP:4553 | Towa Pharmaceutical Co | 3345.00 | 453.77 | 15.69% | |
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1080.00 | -304.25 | -21.98% | |
| JP:4887 | SAWAI GROUP HOLDINGS Co., Ltd. | 1629.00 | -199.65 | -10.92% |
Mochida Pharmaceutical Co., Ltd. Corporate Events
Mochida Pharmaceutical Advances Share Buyback Under ¥2 Billion Authorization
Mochida Pharmaceutical has disclosed progress on its ongoing share repurchase program, acquiring 90,600 of its own common shares on the Tokyo Stock Exchange between July 1 and July 31, 2026, at a total cost of ¥286.4 million via market purchases unde...
Mochida Pharmaceutical Posts Strong Q1 Earnings and Confirms Full-Year Outlook
Mochida Pharmaceutical reported robust results for the three months ended June 30, 2026, with net sales rising 19.1% year on year to ¥31.7 billion and profit attributable to owners of parent surging 67.8% to ¥3.18 billion. Earnings per share climbed...
Mochida Advances Share Buyback Under ¥2 Billion Authorization
Mochida Pharmaceutical has disclosed the latest progress of its share buyback program authorized under Japan’s Companies Act, repurchasing 60,600 common shares for approximately 192.8 million yen via market purchases on the Tokyo Stock Exchange betwe...
Mochida Pharmaceutical Reports Initial Progress on Share Buyback Program
Mochida Pharmaceutical has disclosed the latest progress of its ongoing share repurchase program authorized under Japan’s Companies Act, confirming it bought back 35,300 common shares on the Tokyo Stock Exchange between May 18 and May 31, 2026, at a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026